Article
Medicine, General & Internal
Steven K. K. Grinspoon, Kathleen V. V. Fitch, Markella V. V. Zanni, Carl J. J. Fichtenbaum, Triin Umbleja, Judith A. A. Aberg, Edgar T. T. Overton, Carlos D. D. Malvestutto, Gerald S. S. Bloomfield, Judith S. S. Currier, Esteban Martinez, Jhoanna C. C. Roa, Marissa R. R. Diggs, Evelynne S. S. Fulda, Kayla Paradis, Stephen D. D. Wiviott, Borek Foldyna, Sara E. E. Looby, Patrice Desvigne-Nickens, Beverly Alston-Smith, Jorge Leon-Cruz, Sara McCallum, Udo Hoffmann, Michael T. T. Lu, Heather J. J. Ribaudo, Pamela S. S. Douglas, REPRIEVE Investigators
Summary: This phase 3 trial investigated primary prevention strategies for cardiovascular disease in HIV-infected individuals receiving antiretroviral therapy. The results showed that participants receiving pitavastatin had a lower risk of major adverse cardiovascular events compared to those receiving placebo over a median follow-up of 5.1 years.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Takashi Fujimoto, Yoichi Morofuji, Andrej Kovac, Michelle A. Erickson, Maria A. Deli, Masami Niwa, William A. Banks
Summary: Statins have neuroprotective effects on neurological diseases, possibly through regulating blood-brain barrier function. Pitavastatin (PTV) can ameliorate lipopolysaccharide-induced blood-brain barrier dysfunction by inhibiting cytokine production. These findings highlight the pharmacological significance of statins in the treatment of central nervous system diseases.
Article
Pharmacology & Pharmacy
Nirmala Tilija Pun, Naeun Lee, Sang-Hoon Song, Chul-Ho Jeong
Summary: This study found that pitavastatin can block autophagy flux and induce apoptosis in cancer cells through the accumulation of FOXO3a protein and induction of ER stress.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Peripheral Vascular Disease
Kenichi Tsujita, Koutaro Yokote, Junya Ako, Ryohei Tanigawa, Sachiko Tajima, Hideki Suganami
Summary: This study compared the efficacy and safety of pitavastatin/ezetimibe combination therapy with pitavastatin monotherapy in patients with hypercholesterolemia. The results showed that the combination therapy significantly reduced LDL-C and total cholesterol levels, and had a similar safety profile to pitavastatin monotherapy.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
(2023)
Article
Chemistry, Medicinal
Linda Voss, Karina Guttek, Annika Reddig, Annegret Reinhold, Martin Voss, Luca Simeoni, Burkhart Schraven, Dirk Reinhold
Summary: Pitavastatin, an approved drug, inhibits T-cell proliferation and induces apoptosis, showing potential for treating T-cell-mediated autoimmune diseases.
Article
Medicine, Research & Experimental
Yoon-Hee Cheon, Chang Hoon Lee, Soojin Kim, Gyeong Do Park, Sung Chul Kwak, Hae Joong Cho, Ju-Young Kim, Myeung Su Lee
Summary: Pitavastatin shows potential as a candidate for treating osteoporosis by enhancing osteoblast differentiation and bone growth, as well as inhibiting osteoclast differentiation and bone resorption. Its mechanisms include inhibiting signaling pathways and downregulating transcription factors to regulate osteoclast activity, and stimulating osteoblast differentiation and mineralization to promote bone formation.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Biochemistry & Molecular Biology
Amirhossein Sahebkar, Nasim Kiaie, Armita Mahdavi Gorabi, Massimo R. Mannarino, Vanessa Bainaconi, Tannaz Jamialahmadi, Matteo Pirro, Maciej Banach
Summary: Pitavastatin is a unique lipophilic statin with pleiotropic effects, including reducing inflammation and oxidative stress. It appears to be the safest statin based on available studies, with multiple therapeutic effects that make it an interesting option for the treatment of various human diseases.
PROGRESS IN LIPID RESEARCH
(2021)
Article
Oncology
Debbie Piktel, Javohn C. Moore, Sloan Nesbit, Samuel A. Sprowls, Michael D. Craig, Stephanie L. Rellick, Rajesh R. Nair, Ethan Meadows, John M. Hollander, Werner J. Geldenhuys, Karen H. Martin, Laura F. Gibson
Summary: This study investigates the effects of pitavastatin in chemo-resistant ALL cells and provides evidence for the repurposing of this drug as a potential treatment for eliminating chemoresistant tumor cells. The results demonstrate that pitavastatin inhibits the proliferation of chemo-resistant ALL cells and induces apoptosis, highlighting its potential as a therapeutic agent in the treatment of chemo-resistant ALL.
Article
Environmental Sciences
Ya-Hui Chen, Ying-Chih Huang, Shun-Fa Yang, Hsu-Heng Yen, Horng-Der Tsai, Ming-Chia Hsieh, Yi-Hsuan Hsiao
Summary: The combination treatment of metformin and pitavastatin significantly reduces cell viability, induces cell cycle arrest, and exerts anticancer effects through various pathways, demonstrating a synergistic interaction in pancreatic cancer cells.
ENVIRONMENTAL TOXICOLOGY
(2021)
Article
Pharmacology & Pharmacy
Maged Kharouba, Amal El-Kamel, Radwa Mehanna, Eman Thabet, Lamia Heikal
Summary: This study evaluated the anti-cancer activity of orally delivered pitavastatin loaded in bilosomes and coated with lactoferrin against hepatocellular carcinoma (HCC). It demonstrated improved permeation and cellular uptake of pitavastatin in HCC cells, as well as enhanced cytotoxicity. The optimized formula shows promise as a treatment for HCC.
Article
Engineering, Biomedical
Weizhen Chen, Guoliang Xie, Yang Lu, Jiayuan Wang, Baihuan Feng, Qi Wang, Kui Xu, Jiaqi Bao
Summary: This study focuses on the surface modification of metal implants using pitavastatin to enhance bone defect healing through the synergistic osteogenesis-angiogenesis regulation. The researchers constructed multilayer films with osteogenic and angiogenic properties on pure titanium substrates, and found that locally applied pitavastatin dramatically enhanced the osteogenic potential of mesenchymal stem cells (MSCs) and the angiogenic potential of endothelial cells (ECs). Furthermore, the pitavastatin-loaded films were able to regulate the paracrine signaling between MSCs and ECs, indirectly increasing the angiogenic potential of MSCs and the osteogenic potential of ECs. Subcutaneous and femur implantation experiments confirmed that locally released pitavastatin promoted endogenous stem cells and ECs to the implant-bone interface, facilitating coupled osteogenesis and angiogenesis, and enhancing peri-implant osseointegration.
Article
Neurosciences
Yunhao Wu, Wei Meng, Ming Guan, Xiaolong Zhao, Chen Zhang, Qiaojun Fang, Yuhua Zhang, Zihui Sun, Mingjing Cai, Dongdong Huang, Xuechun Yang, Yafeng Yu, Yong Cui, Shuangba He, Renjie Chai
Summary: This study found that Pitavastatin (PTV) has a protective effect against aminoglycoside-induced hearing loss. PTV reduced hair cell loss and promoted cell survival. Additionally, PTV attenuated endoplasmic reticulum stress in hair cells by inhibiting specific signaling pathways. These results suggest that PTV may be a promising therapeutic agent for treating aminoglycoside-induced ototoxicity.
FRONTIERS IN MOLECULAR NEUROSCIENCE
(2022)
Article
Microbiology
Hidetaka Majima, Teppei Arai, Katsuhiko Kamei, Akira Watanabe
Summary: This study evaluated the in vivo efficacy of pitavastatin combined with itraconazole against Aspergillus fumigatus using silkworm models. The results showed that the combination therapy had a prolonged survival time, reduced hyphal amount, and decreased fungal burden. Unlike most statins, pitavastatin has minimal drug-drug interactions with azoles, making it safe to use. This combination therapy may be a promising option for effective treatment in future clinical settings.
MICROBIOLOGY SPECTRUM
(2023)
Article
Oncology
Mariana Nunes, Diana Duarte, Nuno Vale, Sara Ricardo
Summary: The main challenge in managing high-grade serous carcinoma is overcoming chemoresistance. Combining drugs and repurposing non-oncological agents are attractive strategies. This study explored the therapeutic benefits of combining Paclitaxel with repurposed drugs. The results showed that the combination of Paclitaxel with Pitavastatin or Ivermectin demonstrated the highest cytotoxic effect and strongest synergism in chemoresistant cell lines, suggesting its potential as a valuable strategy for treating ovarian cancer patients with chemoresistance.
Article
Microbiology
Hidetaka Majima, Teppei Arai, Katsuhiko Kamei, Akira Watanabe
Summary: This study evaluated the in vivo efficacy of combining pitavastatin (PIT) with itraconazole (ITC) against Aspergillus fumigatus using silkworm models. The combination therapy showed improved efficacy compared to no treatment and ITC alone, resulting in prolonged survival and reduced fungal burden. Notably, PIT can be safely administered with azoles due to minimal drug-drug interactions. This study highlights the potential of combining PIT with ITC as an effective treatment option in clinical settings.
MICROBIOLOGY SPECTRUM
(2023)
